ADC Therapeutics SA ADCT.N, ADCT.K is expected to show a rise in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
The Epalinges Vaud-based company is expected to report a 2.6% increase in revenue to $17.861 million from $17.41 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 47 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ADC Therapeutics SA is $9.00, about 69.2% above its last closing price of $2.77
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.39 | -0.40 | -0.36 | Beat | 10.7 |
Dec. 31 2025 | -0.44 | -0.41 | -0.29 | Beat | 29.6 |
Sep. 30 2024 | -0.36 | -0.39 | -0.42 | Missed | -6.3 |
Jun. 30 2024 | -0.45 | -0.46 | -0.38 | Beat | 16.9 |
Mar. 31 2024 | -0.55 | -0.56 | -0.56 | Met | -0.8 |
Dec. 31 2023 | -0.48 | -0.50 | -1.03 | Missed | -104.8 |
Sep. 30 2023 | -0.65 | -0.63 | -0.58 | Beat | 8.5 |
Jun. 30 2023 | -0.35 | -0.46 | -0.58 | Missed | -26.9 |
This summary was machine generated August 1 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。